-
Critical Care (London, England) 1999
Topics: Blood Substitutes; Fluorocarbons; Hemoglobins; Humans
PubMed: 11094487
DOI: 10.1186/cc363 -
Annals of the Royal College of Surgeons... Jan 1954
Topics: Blood Substitutes; Convulsive Therapy; Dextrans; Plasma Substitutes
PubMed: 13125237
DOI: No ID Found -
British Journal of Anaesthesia Sep 1973
Review
Topics: Blood Proteins; Blood Volume; Carbon Dioxide; Colloids; Dextrans; Freeze Drying; Gelatin; Humans; Molecular Weight; Oxygen; Plasma Substitutes; Plasma Volume; Pyrrolidinones; Starch
PubMed: 4586030
DOI: 10.1093/bja/45.9.958 -
Critical Care (London, England) 2004Transfusable fluids that may be used as alternatives to red blood cell transfusion offer the promise of preserving tissue perfusion and minimizing hypoxic cellular... (Review)
Review
Transfusable fluids that may be used as alternatives to red blood cell transfusion offer the promise of preserving tissue perfusion and minimizing hypoxic cellular damage, and this promise may soon be fulfilled. Clinical testing of hemoglobin-based oxygen carriers has faced and met challenges involving molecular design, safety, efficacy, and regulatory requirements. Three leading candidates have emerged: two human (PolyHeme and HemoLink) and one bovine-based hemoglobin solution (Hemopure). Because a survival benefit has been difficult to demonstrate, avoidance of allogeneic transfusion has been adopted as the standard efficacy end-point for these agents. An update on clinical trial status is provided, and the potential utility of hemoglobin-based oxygen carriers in surgery combined with intraoperative autologous donation is discussed.
Topics: Animals; Blood Substitutes; Cattle; Erythrocyte Transfusion; Hemoglobins; Humans; Meta-Analysis as Topic
PubMed: 15196328
DOI: 10.1186/cc2455 -
International Journal of Molecular... Sep 2021Amidst the global shortfalls in blood supply, storage limitations of donor blood and the availability of potential blood substitutes for transfusion applications,... (Review)
Review
Amidst the global shortfalls in blood supply, storage limitations of donor blood and the availability of potential blood substitutes for transfusion applications, society has pivoted towards in vitro generation of red blood cells (RBCs) as a means to solve these issues. Many conventional research studies over the past few decades have found success in differentiating hematopoietic stem and progenitor cells (HSPCs) from cord blood, adult bone marrow and peripheral blood sources. More recently, techniques that involve immortalization of erythroblast sources have also gained traction in tackling this problem. However, the RBCs generated from human induced pluripotent stem cells (hiPSCs) still remain as the most favorable solution due to many of its added advantages. In this review, we focus on the breakthroughs for high-density cultures of hiPSC-derived RBCs, and highlight the major challenges and prospective solutions throughout the whole process of erythropoiesis for hiPSC-derived RBCs. Furthermore, we elaborate on the recent advances and techniques used to achieve cost-effective, high-density cultures of GMP-compliant RBCs, and on their relevant novel applications after downstream processing and purification.
Topics: Blood Substitutes; Cell Differentiation; Erythrocyte Transfusion; Erythrocytes; Erythropoiesis; Fetal Blood; Hematopoietic Stem Cells; Humans; Induced Pluripotent Stem Cells
PubMed: 34575977
DOI: 10.3390/ijms22189808 -
EBioMedicine Jun 2016
Topics: Blood Banks; Blood Donors; Blood Substitutes; Humans; Transfusion Medicine
PubMed: 27428400
DOI: 10.1016/j.ebiom.2016.06.004 -
Scientific Reports Nov 2016There is no blood bank for pet animals. Consequently, veterinarians themselves must obtain "blood" for transfusion therapy. Among the blood components, serum albumin and...
There is no blood bank for pet animals. Consequently, veterinarians themselves must obtain "blood" for transfusion therapy. Among the blood components, serum albumin and red blood cells (RBCs) are particularly important to save lives. This paper reports the synthesis, structure, and properties of artificial blood for the exclusive use of dogs. First, recombinant canine serum albumin (rCSA) was produced using genetic engineering with Pichia yeast. The proteins showed identical features to those of the native CSA derived from canine plasma. Furthermore, we ascertained the crystal structure of rCSA at 3.2 Å resolution. Pure rCSA can be used widely for numerous clinical and pharmaceutical applications. Second, hemoglobin wrapped covalently with rCSA, hemoglobin-albumin cluster (Hb-rCSA), was synthesized as an artificial O-carrier for the RBC substitute. This cluster possesses satisfactorily negative surface net charge (pI = 4.7), which supports enfolding of the Hb core by rCSA shells. The anti-CSA antibody recognized the rCSA exterior quantitatively. The O-binding affinity was high (P = 9 Torr) compared to that of the native Hb. The Hb-rCSA cluster is anticipated for use as an alternative material for RBC transfusion, and as an O therapeutic reagent that can be exploited in various veterinary medicine situations.
Topics: Animals; Blood Substitutes; Crystallography, X-Ray; Dogs; Hemoglobins; Models, Molecular; Oxygen; Protein Binding; Protein Conformation, alpha-Helical; Protein Domains; Protein Stability; Serum Albumin
PubMed: 27830776
DOI: 10.1038/srep36782 -
Anaesthesiology Intensive Therapy 2018Fluid therapy is one of the most important treatments in patients with traumatic brain injury (TBI) as both hypo- and hypervolaemia can cause harm. The main goals of... (Review)
Review
Fluid therapy is one of the most important treatments in patients with traumatic brain injury (TBI) as both hypo- and hypervolaemia can cause harm. The main goals of fluid therapy for patients with TBI are to optimize cerebral perfusion and to maintain adequate cerebral oxygenation. The avoidance of cerebral oedema is clearly essential. The current weight of evidence in the published literature suggests that albumin therapy is harmful and plasma substitutes have failed to demonstrate superiority over crystalloids solutions. Crystalloids are the most common fluids administered in patients with TBI. However, differences in their composition may affect coagulation and plasma tonicity and acid-base homeostasis. The choice of the ideal crystalloid fluid in TBI should be made based on tonicity, type of buffer used and volume status. Hypotonic fluids buffered with substances altering blood coagulation should be avoided in clinical practice. The prescriber remains faced with choices about the tonicity and pH buffering capability of fluid therapy, which we review here.
Topics: Brain Injuries, Traumatic; Crystalloid Solutions; Fluid Therapy; Humans; Plasma Substitutes
PubMed: 29165777
DOI: 10.5603/AIT.a2017.0067 -
The Western Journal of Medicine Aug 1985Because of the risks and costs of blood and blood product infusion, developing blood and plasma substitutes is of significance. Two currently utilized substances,... (Review)
Review
Because of the risks and costs of blood and blood product infusion, developing blood and plasma substitutes is of significance. Two currently utilized substances, dextran and hydroxyethyl starch, are effective colloid plasma expanders. The dextrans have properties that improve microcirculatory blood flow but are associated with several possible adverse effects. Hydroxyethyl starch is a well-tolerated agent that has efficacy similar to albumin but at a lower cost. Two newer substances, perfluorocarbons and stroma-free hemoglobin, are being developed to improve oxygen transport as well as plasma expansion.
Topics: Blood Substitutes; Blood Volume; Dextrans; Fluorocarbons; Hemoglobins; Humans; Hydroxyethyl Starch Derivatives; Oxygen
PubMed: 2412350
DOI: No ID Found -
Journal of Vascular Surgery Dec 2018
Topics: Blood Substitutes
PubMed: 30470353
DOI: 10.1016/j.jvs.2017.10.058